Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Intangibles (2016 - 2026)

Usana Health Sciences (USNA) has disclosed Intangibles for 16 consecutive years, with $133.2 million as the latest value for Q1 2026.

  • Quarterly Intangibles fell 12.3% to $133.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $133.2 million through Jan 2026, down 12.3% year-over-year, with the annual reading at $133.2 million for FY2026, 12.3% down from the prior year.
  • Intangibles for Q1 2026 was $133.2 million at Usana Health Sciences, down from $138.2 million in the prior quarter.
  • The five-year high for Intangibles was $151.8 million in Q4 2024, with the low at $28.6 million in Q2 2024.
  • Average Intangibles over 5 years is $63.6 million, with a median of $32.0 million recorded in 2023.
  • The sharpest move saw Intangibles dropped 25.67% in 2022, then surged 407.45% in 2024.
  • Over 5 years, Intangibles stood at $32.4 million in 2022, then decreased by 7.75% to $29.9 million in 2023, then soared by 407.45% to $151.8 million in 2024, then dropped by 9.0% to $138.2 million in 2025, then dropped by 3.62% to $133.2 million in 2026.
  • According to Business Quant data, Intangibles over the past three periods came in at $133.2 million, $138.2 million, and $142.7 million for Q1 2026, Q3 2025, and Q2 2025 respectively.